Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.

• Status: Completed
• Trial end date: 2021-07-20
• Target enrollment: 0
• Participant gender: All

Summary

Pain after laparoscopy differs considerably from that seen after laparotomy. Laparotomy results mainly in parietal pain (abdominal wall), where as Pain in laparoscopy results from stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic irritation caused by residual carbon-dioxide in the peritoneal cavity. The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). While esmolol is an ultra-short acting intravenous β-blocker having a rapid onset and offset effect. It provides an unprecedented level of tolerability and safety in the perioperative setting. When used as an adjunct, it has been shown to improve the postoperative recovery by reducing postoperative pain intensity and intraoperative anesthetic and opioid requirements and preventing opioid-induced hyperalgesia . The mechanism of this synergistic effect is uncertain, but both pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Esmolol

Criteria

Inclusion Criteria:

1. ASA grade I/II patients undergoing laparoscopic cholecystectomy .

2. Age group of 18 -60 years.

3. Patients giving valid informed consent.

Exclusion Criteria:

1. Patient refusal

2. Patients belonging to ASA grade III and grade IV .

3. Coagulation disorders.

4. Patients with known allergy to one of the used drugs.

5. Extreme obesity (BMI >35)

6. Patients with cardiac, pulmonary, hepatic or renal disorders

7. Pregnancy

8. Drug abusers